StephenPRichmanMD

PubMed

• 115 citations
  Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
  Lynn G. Feun, Ying-Ying Li, Chunjing Wu, Medhi Wangpaichitr, Patricia D. Jones, Stephen P. Richman, Beatrice L. Madrazo, Deukwoo Kwon, Monica T. Garcia-Buitrago, Paul ...> ;Cancer. 2019 Oct 15
• 10 citations
  Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
  Lynn G. Feun, Medhi Wangpaichitr, Ying-Ying Li, Deukwoo Kwon, Stephen P. Richman, Peter J. Hosein, Niramol Savaraj> ;Journal of Hepatocellular Carcinoma. 2018 Jan 12
• 30 citations
  Levels of Symptom Burden During Chemotherapy for Advanced Lung Cancer: Differences Between Public Hospitals and a Tertiary Cancer Center
  Charles S. Cleeland, Tito R. Mendoza, Xin Shelley Wang, Jeanie F. Woodruff, Guadalupe R. Palos, Stephen P. Richman, Arlene Nazario, Garrett R. Lynch, Kai Ping Liao, Ga...> ;Journal of Clinical Oncology. 2011 Jul 20
• Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study.
  Maughan T, Wilson RH, Williams GT, Seymour MT, Richman S, Quirke P, Pope M, Pope J, Parmar M, Nelson A, Meade AM, Kenny SL, Jasani B, Hodgkinson E, Fisher D, Butler R,...> ;J. Clin. Oncol.. 2011-05-20
• Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).
  Seymour MT, Brown SR, Richman S, Middleton GW, Maughan T, Olivier C, Gwyther SJ, Wadsley J, Chau I, Hickish T, Dawson LK, Falk S, O'Callaghan A, Benstead K, Wadd N, Ol...> ;J. Clin. Oncol.. 2011-05-20
• Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).
  Middleton GW, Gwyther SJ, Brown SR, Maughan T, Olivier C, Richman S, Maisey NR, Hill M, Gollins S, Myint S, Slater S, Wagstaff J, Bridgewater JA, Glynne-Jones R, Hemmi...> ;J. Clin. Oncol.. 2011-05-20
• 58 citations
  Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
  C. Lobo, Gilberto Lopes, Odalys Baez, Aurelio Castrellon, Annapoorna Ferrell, Connie Higgins, Erin Hurley, Judith Hurley, Isildinha Reis, Stephen P. Richman, Pearl Seo...> ;Breast Cancer Research and Treatment. 2010 Jun 29
• Prognostic value of thymidylate synthase (TS) expression on failure-free survival of fluorouracil-treated metastatic colorectal cancer patients.
  Richman S, Braun MS, Adlard JW, Daly C, Turner F, Barrett J, Meade A, Parmar M, Quirke P, Seymour MT> ;J. Clin. Oncol.. 2006-06-20
• Endoscopic ultrasound downstage after neoadjuvant chemotherpy predicts survival of locally advanced esophageal cancer.
  Ribeiro A, Livingstone A, Franceschi D, Richman S, Lima M, Parra J, Hamilton K, Ardalan B> ;J. Clin. Oncol.. 2005-06-01
• 75 citations
  Pain Education for Underserved Minority Cancer Patients: A Randomized Controlled Trial
  Karen O. Anderson, Tito R. Mendoza, Richard Payne, Vicente Valero, Guadalupe R. Palos, Arlene Nazario, Stephen P. Richman, Judith Hurley, Ibrahima Gning, Garrett R. Ly...> ;Journal of Clinical Oncology. 2004 Dec 15
• 171 citations
  Cancer pain management among underserved minority outpatients: perceived needs and barriers to optimal control.
  Karen O. Anderson, Stephen P. Richman, Judith Hurley, Guadalupe R. Palos, Vicente Valero, Tito R. Mendoza, Ibrahima Gning, Charles S. Cleeland> ;Cancer. 2002 Apr 15
• 247 citations
  Minority cancer patients and their providers: pain management attitudes and practice.
  Karen O. Anderson, Tito R. Mendoza, Vicente Valero, Stephen P. Richman, Christy A. Russell, Judith Hurley, Cindy DeLeon, Patricia Washington, Guadalupe R. Palos, Richa...> ;Cancer. 2000 Apr 15
• 29 citations
  A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma.
  Louise E. Morrell, Young J. Lee, Judith Hurley, Mayda Arias, Carolyn Mies, Stephen P. Richman, Hugo F. Fernandez, Kim A. Donofrio, William A. Raub, Peter A. Cassileth> ;Cancer. 1998 Feb 1
• 1 citations
  Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest ...
  Roy L. Martino, Thomas R. Fleming, L Morrell, Bach Ardalan, Stephen P. Richman> ;Investigational New Drugs. 1996 Jan 1
• 5 citations
  A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study
  R. P. Whitehead, M. K. Wolf, D. L. Solanki, George P. Hemstreet, Pasquale Benedetto, Stephen P. Richman, Robert C. Flanigan, E. D. Crawford> ;Journal of Immunotherapy With Emphasis on Tumor Immunology. 1995 Aug 1
• 11 citations
  Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
  Lynn G. Feun, Niramol Savaraj, Frederick L. Moffat, David S. Robinson, Amy Liebmann, Judith Hurley, William A. Raub, Stephen P. Richman> ;Melanoma Research. 1995 Aug 1
• 10 citations
  Phase I trial of low dose N‐phosphonacetyl‐L‐aspartic acid and high dose 5‐fluorouracil administered concomitantly with radiation therapy for unresectable localized ad...
  Bach Ardalan, Antonio Ucar, Rajender Reddy, Alan S. Livingstone, Arnold M. Markoe, James G. Schwade, Stephen P. Richman, Kim A. Donofrio> ;Cancer. 1994 Oct 1
• 5 citations
  Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.
  Alexander Hantel, Catherine M. Tangen, Stephen P. Richman, Reginald P. Pugh, Theodore W. Pollock> ;Investigational New Drugs. 1994 Jan 1
• 2 citations
  Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. A Southwest Oncology Group trial.
  Sarah A. Taylor, Jacqueline Benedetti, David E. Schuller, Stephen P. Richman, G. O. Broun, Alexander Hantel> ;Investigational New Drugs. 1993 May 1
• 12 citations
  Phase II trial of 4′-O-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma
  Kasi S. Sridhar, Atif M. Hussein, Pasquale Benedetto, Bach Ardalan, Niramol Savaraj, Stephen P. Richman> ;Cancer. 1992 Sep 15
• 19 citations
  Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
  Bach Ardalan, Kasi Stridhar, Rajender Reddy, Pasquale Benedetto, Stephen P. Richman, Stuart Waldman, L Morrell, Lynn G. Feun, Niramol Savaraj, Alan S. Livingstone> ;International Journal of Radiation Oncology, Biology, Physics. 1992 Jan 1
• 109 citations
  Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
  Rasim Gucalp, P Ritch, Peter H. Wiernik, P R Sarma, A Keller, Stephen P. Richman, K Tauer, J Neidhart, L E Mallette, R Siegel> ;Journal of Clinical Oncology. 1992 Jan 1
• 17 citations
  Lung carcinoma in 1,336 patients.
  Kasi S. Sridhar, William A. Raub, Robert C. Duncan, Susan G. Hilsenbeck, Stephen P. Richman> ;American Journal of Clinical Oncology. 1991 Dec 1
• 10 citations
  A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
  Bach Ardalan, Kasi S. Sridhar, Pasquale Benedetto, Stephen P. Richman, Stuart Waldman, L Morrell, Lynn G. Feun, Niramol Savaraj, Miguel Fodor, Alan S. Livingstone> ;Cancer. 1991 Sep 15
• 5 citations
  Phase II trial of mitoxantrone in head and neck carcinoma.
  Kasi S. Sridhar, Atif M. Hussein, Pasquale Benedetto, Stuart Waldman, Lynn G. Feun, Niramol Savaraj, Stephen P. Richman, Bach Ardalan, Purina Desai> ;American Journal of Clinical Oncology. 1991 Aug 1
• Join now to see all